Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma
Radiology · 01.11.2026 · 321 (2)
DOI: 10.1148/radiol.260517 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Radiology, erschienen am 01.11.2026. Verfasst von Gary A Ulaner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Imaging and Therapy, Hoag Family Cancer Institute, 16105 Sand Canyon Ave, Irvine, CA 92618. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Zirconium, Multiple Myeloma, ADP-ribosyl Cyclase 1. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Institutes of Health, Sylvester Comprehensive Cancer Center.
Abstract (Originalsprache)
In participants with multiple myeloma, CD38-targeted zirconium 89 deferoxamine-daratumumab immuno-PET/CT helped detect active myeloma, even in some participants with no signs of disease at fluorine 18 fluorodeoxyglucose PET/CT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Imaging and Therapy, Hoag Family Cancer Institute, 16105 Sand Canyon Ave, Irvine, CA 92618.
- Department of Radiology and Cancer Biology, University of Southern California, Los Angeles, Calif.
- Department of Radiology, University of Miami Miller School of Medicine, Miami, Fla.
- Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Fla.
- Department of Medical Oncology, Hoag Family Cancer Institute, Irvine, Calif.
- Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, Calif.
ORCID-Profile: Gary A Ulaner, Russ A Kuker, Benjamin Diamond, Ben Goldenson, Beth Thomsen, Alanna Vossen, Dickran Kazandjian
Förderung
- National Institutes of Health
- Sylvester Comprehensive Cancer Center
Zitieren
APA
Ulaner, G. A., Kuker, R. A., Diamond, B., Hoffman, J., Motwani, P., Goldenson, B., Homsi, Y., Schiller, G., Thomsen, B., Vossen, A., Kazandjian, D., & Landgren, C. O. (2026). Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma. Radiology, 321(2). https://doi.org/10.1148/radiol.260517
Vancouver
Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, et al. Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma. Radiology. 2026;321(2). doi:10.1148/radiol.260517
BibTeX
@article{Ulaner2026,
author = {Ulaner, Gary A and Kuker, Russ A and Diamond, Benjamin and Hoffman, James and Motwani, Pooja and Goldenson, Ben and Homsi, Yaser and Schiller, Gary and Thomsen, Beth and Vossen, Alanna and Kazandjian, Dickran and Landgren, C Ola},
title = {Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma},
journal = {Radiology},
year = {2026},
volume = {321},
number = {2},
doi = {10.1148/radiol.260517}
}
EUVIMED